IPI-549-01 - A Phase 1/1b, first-inhuman study of IPI-549, a PI3K-γ inhibitor, as monotherapy and in combination with nivolumab in patients with advanced solid tumors

Authors
Category Primary study
JournalCancer Research
Year 2017
This article has no abstract
Epistemonikos ID: a89b4060404c1c1a8ca6fa7b9c4111d51f21ea92
First added on: Feb 08, 2025